IMMX
Price
$1.64
Change
+$0.07 (+4.46%)
Updated
Apr 14, 04:27 PM (EDT)
Capitalization
43.39M
44 days until earnings call
SYRE
Price
$13.08
Change
+$0.86 (+7.04%)
Updated
Apr 14, 04:46 PM (EDT)
Capitalization
736.34M
24 days until earnings call
Ad is loading...

IMMX vs SYRE

Header iconIMMX vs SYRE Comparison
Open Charts IMMX vs SYREBanner chart's image
Immix Biopharma
Price$1.64
Change+$0.07 (+4.46%)
Volume$100
Capitalization43.39M
Spyre Therapeutics
Price$13.08
Change+$0.86 (+7.04%)
Volume$100
Capitalization736.34M
IMMX vs SYRE Comparison Chart
Loading...
IMMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMMX vs. SYRE commentary
Apr 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMMX is a Hold and SYRE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 14, 2025
Stock price -- (IMMX: $1.57 vs. SYRE: $12.22)
Brand notoriety: IMMX and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMMX: 84% vs. SYRE: 82%
Market capitalization -- IMMX: $43.39M vs. SYRE: $736.34M
IMMX [@Biotechnology] is valued at $43.39M. SYRE’s [@Biotechnology] market capitalization is $736.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMMX’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • IMMX’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, IMMX is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMMX’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • IMMX’s TA Score: 4 bullish, 6 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than IMMX.

Price Growth

IMMX (@Biotechnology) experienced а +4.33% price change this week, while SYRE (@Biotechnology) price change was -4.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.28%. For the same industry, the average monthly price growth was -13.99%, and the average quarterly price growth was -22.43%.

Reported Earning Dates

IMMX is expected to report earnings on Sep 03, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($736M) has a higher market cap than IMMX($43.4M). IMMX YTD gains are higher at: -28.864 vs. SYRE (-47.509). IMMX has higher annual earnings (EBITDA): -22.41M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. IMMX (19.7M). SYRE has less debt than IMMX: SYRE (0) vs IMMX (1.09M). IMMX (0) and SYRE (0) have equivalent revenues.
IMMXSYREIMMX / SYRE
Capitalization43.4M736M6%
EBITDA-22.41M-208.57M11%
Gain YTD-28.864-47.50961%
P/E RatioN/A1.72-
Revenue00-
Total Cash19.7M603M3%
Total Debt1.09M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
72
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IMMXSYRE
RSI
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 21 days ago
82%
Bullish Trend 18 days ago
86%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Ad is loading...
IMMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PIEFX15.090.43
+2.93%
Federated Hermes Emerging Markets Eq IS
ACARX27.670.46
+1.69%
Alger Capital Appreciation Instl R
SGICX16.090.20
+1.26%
SGI US Large Cap Equity C
CGRYX30.110.35
+1.18%
Invesco Comstock Select Y
BIICX9.840.03
+0.31%
BlackRock Multi-Asset Income Instl

IMMX and

Correlation & Price change

A.I.dvisor tells us that IMMX and ABOS have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMMX and ABOS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMMX
1D Price
Change %
IMMX100%
+6.97%
ABOS - IMMX
29%
Poorly correlated
+8.82%
SYRE - IMMX
29%
Poorly correlated
+2.43%
OCUL - IMMX
28%
Poorly correlated
+11.01%
IMTX - IMMX
28%
Poorly correlated
+4.28%
GOSS - IMMX
28%
Poorly correlated
+6.18%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with APGE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+2.43%
APGE - SYRE
51%
Loosely correlated
+6.21%
CGON - SYRE
50%
Loosely correlated
+9.36%
PRME - SYRE
48%
Loosely correlated
+13.68%
IMNM - SYRE
48%
Loosely correlated
+14.52%
ACLX - SYRE
48%
Loosely correlated
+4.39%
More